The French pharma company Servier has signed an agreement with BioInvent International on the collaboration of conducting discovery research for potential antibody treatment of cancer.
The partnership will collaborate on one of Servier’s oncology target that involved in tumour cell metabolism. Details of the target mechanism was not disclosed. Servier will have access to BioInvent’s proprietary n-CoDeR library, which contains more than 20 billion highly diverse, fully human antibody fragments, for specific antibodies against the oncology target.
Servier will be able to use BioInvent’s in-house pre-clinical capacities in selecting an antibody candidate for further development. In return, the Swedish biotech BioInvent will receive a licensing fee, research support and potential milestone payments of more than 11 million euros and potential sales royalties.
The alliance expectes the joint research can lead to the development the first monoclonal antibodies targeting tumour cell metabolism, an approach anticipated to have strong therapeutic potential for cancer.
”With this new collaboration Servier will reinforce its capacity of using biologics to address very innovative targets for treating cancer and we are looking forward to benefiting from Bioinvent’s experience,” said Dr Emmanuel Canet, president of Servier.
Svein Mathisen, President and CEO of BioInvent, said: “We believe Servier is an excellent partner for this research project in antibody discovery and research. Oncology is a prioritized area for BioInvent as for Servier and we look forward to joining our knowledge to theirs in this area.”
The Swedish biotech firm BioInvent has a pipeline focused on innovative antibody drugs targeting cancer, thrombosis, atherosclerosis, and inflammatory diseases. The company is currently collaborating with Genentech, Human Genome Sciences, Roche and ThromboGenics. Last December, the biotech firm and its partner ThromboGenics have finished the the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery.
- Servier gains development rights of Xoma’s top anti-inflammatory drug
- Sanofi to license in antibody technology for cancer drug research
- Elan and Boehringer Ingelheim collaborate on antibody-based therapeutics
- Sanofi and Merck KGaA collaborate on combo cancer therapies
- AstraZeneca to collaborate with CRUK on cancer trials